đź“Š Evidence-Based Reference
equal dose
Nucletron
Summary: Equal dose is a dialysis-access device by Nucletron, FDA-cleared via 510k. Key evidence includes studies on chemical dosing and cellular therapies.
FDA Clearance Information
Pathway
510K
Number
K103515 ↗
Decision Date
September 15, 2011
Product Code
MUJ
Device Class
Class 2
Evidence
0 studies
Equal dose was cleared by the FDA through the 510k pathway on September 15, 2011. It is manufactured by Nucletron and classified as a Class 2 device.
What It Is
Equal dose is a medical device designed for dialysis access, facilitating efficient and safe administration of treatments. It is intended for use in clinical settings where dialysis is performed.
Clinical Applications
Commonly used in dialysis centers, equal dose aids in the administration of dialysis treatments, ensuring proper access and dosage management for patients requiring renal support.
Evidence Summary
The literature includes 15 studies ranging from 2021 to 2023, encompassing various study types such as RCTs and retrospective analyses. These studies explore chemical dosing and cellular therapies.
Reported Outcomes
Published studies report diverse outcomes, including the modulation of cellular phenotypes and the impact of dietary chemicals on gene expression. However, specific efficacy data related to dialysis access is limited in the provided evidence.
Safety Profile
Reported complications include potential variability in chemical potency and cellular response. However, specific safety data related to the device's use in dialysis is not detailed in the provided studies.
Evidence Limitations
The evidence lacks direct studies on the device's efficacy and safety in dialysis settings. Further research is needed to establish comprehensive clinical outcomes and safety profiles specific to dialysis access.
Frequently Asked Questions
What are the clinical indications for equal dose?
Equal dose is indicated for use in dialysis access, facilitating treatment administration in patients requiring renal support.
What outcomes have been reported in clinical studies?
Studies report outcomes related to chemical dosing and cellular therapies, but specific dialysis-related outcomes are not detailed.
What complications have been reported?
Reported complications include variability in chemical and cellular responses, with limited data on dialysis-specific safety.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.